Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis. Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple interacting cell types. Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Learn more about our technology platform [www.cernostics.com] and how it will change the future of cancer diagnostics.